Home/Pipeline/CUG252

CUG252

Autoimmune and Inflammatory Diseases

Pre-clinicalActive

Key Facts

Indication

Autoimmune and Inflammatory Diseases

Phase

Pre-clinical

Status

Active

Company

Cugene

About Cugene

Cugene is a private, clinical-stage biotech founded in 2018, focusing on precision-engineered immunotherapies for autoimmune diseases and cancer. Its core technology platform involves immuno-engineering to create selective biologics, including engineered cytokines and bispecific antibodies with proprietary masking domains. The lead program, CUG252, is a Treg-selective IL-2 for autoimmune conditions, while its oncology pipeline features TILKine™ and VitoKine™ bispecific platforms designed to transform cold tumors. The company is science-driven, led by an experienced team, and is currently in the pre-clinical to early clinical development stage.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Autoimmune and Inflammatory Diseases Drugs

Drug	Company	Phase	Status
Foldikine™ Platform Pipeline	Orikine Bio	Preclinical	Active
CD31-ITAM Bispecific Platform	Tridek-One	Pre-clinical	Active
CUE-401	Cue Biopharma	Preclinical	Active